Welcome to the UPF Digital Repository

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Show simple item record

dc.contributor.author Curto-Barredo, Laia
dc.contributor.author Duran Jordà, Xavier, 1974-
dc.contributor.author Giménez Arnau, Anna Maria
dc.date.accessioned 2018-10-22T07:33:52Z
dc.date.issued 2018
dc.identifier.citation Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212. DOI: 10.1111/bjd.16379
dc.identifier.issn 0007-0963
dc.identifier.uri http://hdl.handle.net/10230/35625
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley-Blackwell
dc.rights This is the pre-peer reviewed version of the following article: urto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212., which has been published in final form at http://dx.doi.org/10.1111/bjd.16379. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
dc.subject.other Urticària -- Tractament
dc.title Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1111/bjd.16379
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion
dc.embargo.liftdate 2019-07-31
dc.date.embargoEnd info:eu-repo/date/embargoEnd/2019-07-31


This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking